Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Nuocheng Pharmaceutical is a Chinese biotechnology company specializing in the development and manufacture of human vaccines, most notably the human rabies vaccine (Vero cell). As a key subsidiary of Liaoning Cheng Da Biotechnology (Chengda Bio), the company operates significant manufacturing facilities in Shanghai that adhere to national GMP standards. The company's rabies vaccine is a market leader in China, known for its high safety profile and efficacy in post-exposure prophylaxis. Shanghai Nuocheng's integration into the Chengda Bio group has established it as a critical component of one of the world's largest vaccine production platforms. The company continues to focus on biological manufacturing excellence to support public health initiatives in rabies prevention.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai NuoCheng Pharm.